Bernardo Wealth Planning LLC lowered its holdings in shares of Celgene Co. (NASDAQ:CELG) by 19.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,445 shares of the biopharmaceutical company’s stock after selling 596 shares during the period. Bernardo Wealth Planning LLC’s holdings in Celgene were worth $242,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also made changes to their positions in CELG. First PREMIER Bank purchased a new stake in shares of Celgene during the third quarter worth about $26,000. Liberty Wealth Management LLC grew its holdings in shares of Celgene by 212.8% during the second quarter. Liberty Wealth Management LLC now owns 294 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 200 shares in the last quarter. B & T Capital Management DBA Alpha Capital Management purchased a new stake in shares of Celgene during the third quarter worth about $28,000. Massey Quick Simon & CO. LLC purchased a new stake in shares of Celgene during the second quarter worth about $33,000. Finally, Lenox Wealth Advisors LLC purchased a new stake in shares of Celgene during the third quarter worth about $37,000. Institutional investors own 72.31% of the company’s stock.
Celgene stock opened at $108.24 on Thursday. Celgene Co. has a 1 year low of $58.59 and a 1 year high of $109.07. The firm has a 50 day moving average price of $102.13 and a 200 day moving average price of $96.60. The company has a market cap of $76.72 billion, a price-to-earnings ratio of 10.95, a PEG ratio of 0.55 and a beta of 1.41. The company has a debt-to-equity ratio of 1.51, a quick ratio of 2.80 and a current ratio of 2.89.
Celgene (NASDAQ:CELG) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported $2.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.70 by $0.29. Celgene had a net margin of 34.63% and a return on equity of 78.15%. The firm had revenue of $4.52 billion during the quarter, compared to the consensus estimate of $4.39 billion. During the same period in the previous year, the firm earned $2.29 earnings per share. Celgene’s revenue was up 16.1% compared to the same quarter last year. Sell-side analysts predict that Celgene Co. will post 10.7 EPS for the current year.
In related news, insider Terrie Curran sold 11,338 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $98.27, for a total value of $1,114,185.26. Following the completion of the sale, the insider now directly owns 13,493 shares in the company, valued at $1,325,957.11. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.39% of the stock is currently owned by insiders.
A number of equities research analysts have recently commented on CELG shares. ValuEngine downgraded shares of Celgene from a “sell” rating to a “strong sell” rating in a report on Thursday, August 1st. Robert W. Baird downgraded shares of Celgene from an “outperform” rating to a “neutral” rating and set a $101.00 price target for the company. in a report on Friday, November 1st. Wells Fargo & Co set a $110.00 price target on shares of Celgene and gave the stock a “hold” rating in a report on Friday, November 1st. Leerink Swann set a $115.00 price target on shares of Celgene and gave the stock a “hold” rating in a report on Friday, November 1st. Finally, Standpoint Research downgraded shares of Celgene from a “buy” rating to a “hold” rating in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, nineteen have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. Celgene has a consensus rating of “Hold” and an average target price of $97.31.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Read More: What Does a Sell-Side Analyst Rating Mean?
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.